{
    "nct_id": "NCT03070782",
    "official_title": "A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)",
    "inclusion_criteria": "* Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or peripheral artery disease\n* Lp(a) plasma level â‰¥ 60 mg/dL\n* Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD risk factors\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/TIA\n* Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis\n* Heart failure New York Heart Association (NYHA) class IV",
    "miscellaneous_criteria": "Key"
}